MedTrace Logo

Treatment of Breakthrough Cancer Pain According to European Guidelines

NCT04468490 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 131

Last updated 2021-10-27

No results posted yet for this study

Summary

Pain is a frequent symptom in cancer patients with a negative impact on the quality of life (QoL).Breakthrough cancer pain (BTcP) is defined as "a transient exacerbation of pain, manifesting spontaneously or related to a specific predictable or unpredictable triggering factor, despite stable and adequately controlled basal pain". The present study assesses the percentage of patients who are treated according to the European guidelines (ESMO, 2018) for BTcP management in 4 European countries and the impact of the adherence to guidelines on patients' pain relief and QoL.

Conditions

  • Breakthrough Cancer Pain

Sponsors & Collaborators

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-11
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04468490 on ClinicalTrials.gov